SuperGen, Inc. (NASDAQ: SUPG) is focused on building a global, sustainable business by developing and commercializing new drug candidates for oncologists, hematologists, and their patients. The company’s staff is made up of talented individuals who recognize the incredible challenges of drug development. Although some work along and other on teams, each employee brings a distinct perspective to his or her job and is focused on the goal of bringing better products to cancer patients in need. For further information, visit the Company’s web site at www.sunesis.com.
- 17 years ago
QualityStocks
SuperGen, Inc. (NASDAQ: SUPG)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…